Cost Effectiveness of Chimeric Antigen Receptor T-Cell ...
2019-6-3 · Two anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapies are approved for diffuse large B-cell lymphoma, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel; each costs 373,000. We evaluated their cost effectiveness.
Get Price